OYE Therapeutics Secures $5.475 Million Series A Funding for Caffeine-Based Anesthesia Recovery and Overdose Reversal Therapy

OYE Therapeutics announced it raised $5.475 million in a Series A financing on November 28, 2025, to advance clinical development of its high-concentration caffeine therapy for anesthesia recovery and opioid-induced respiratory depression reversal. The clinical-stage pharmaceutical company plans to begin a Phase 1 clinical trial in the first quarter of 2026 for its proprietary product, which represents a novel approach to addressing critical unmet needs in patient care. The financing was oversubscribed, indicating strong investor interest in the company's platform technology that targets both anesthesia recovery and military or civilian acute care applications.

The investigational therapy is designed to work alongside existing treatments like naloxone, aiming to support wakefulness and respiratory drive during recovery from opioid-induced respiratory depression. This approach addresses the growing crisis of fentanyl-related intoxication through a mechanism distinct from current reversal agents. The company's work builds on preclinical research and has received support through U.S. military grant funding, highlighting the potential applications in both civilian and military healthcare settings. WBB Securities LLC served as the placement agent for this transaction, bringing their expertise in life sciences investment banking to facilitate the successful financing round.

The funding will enable OYE Therapeutics to advance its caffeine platform toward clinical validation, with the Phase 1 trial representing a critical milestone in demonstrating safety and preliminary efficacy. The company's focus on transforming overlooked clinical problems into solvable challenges reflects a growing trend in pharmaceutical development toward addressing persistent gaps in patient care. By targeting anesthesia recovery and opioid overdose reversal with a single platform, OYE Therapeutics aims to create versatile therapeutic options that could improve outcomes across multiple clinical scenarios. The company's name, standing for "Open Your Eyes," metaphorically represents both the clinical necessity of restoring consciousness and the innovative vision driving their development approach.

The successful Series A financing demonstrates investor confidence in OYE Therapeutics' strategy and technology platform at a time when healthcare systems face increasing challenges related to anesthesia management and opioid safety. As the company progresses toward clinical trials, its work could potentially offer new tools for healthcare providers managing complex recovery scenarios. The integration of caffeine-based therapy with existing treatments like naloxone represents a complementary approach that could enhance current standard of care protocols. With the funding secured and clinical trials on the horizon, OYE Therapeutics is positioned to advance its novel therapeutic platform toward addressing serious unmet needs in patient care through innovative pharmaceutical development.